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Summary We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of
bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192 consecutive-patients with advanced colorectal carcinoma. On day 1, all patients
received 200 mg m-2 offolinic acid infusion over 2 h. Cohort A (n = 102 patients) received 500 mg m-2 5-FU by i.v. 15-min infusion followed by
an infusion of 500 mg m-2 5-FU over 22 h. Treatment was repeated on day 2 and further cycles given 2-weekly. After sequential analysis
excluded a response rate of over40%, cohort B (n = 90 patients) received an increased dose of 600 mg m-2 5-FU bolus and infusion. Patients
had received no prior 5-FU therapy and the two cohorts had similar demographic features. In 179 evaluable patients, the overall response
rate was 18% (95% Cl 12-24%) with CR of 6% and PR of 12%, with no difference between the two cohorts. Overall median survival was 34
weeks (95% Cl 30-39) with no significant difference between cohorts (median survival 32 and 37 weeks in cohort A and B respectively;
P = 0.27). On multivariate analysis, poor performance status, elevated initial WBC and alkaline phosphatase and low serum albumin were
associated with reduced survival (P < 0.05), and initial raised WBC showed an association with reduced likelihood of response (P= 0.002).
Overall toxicity was low with CTC grade 3 mucositis, diarrhoea, nausea or vomiting in < 6% of patients and no treatment-related deaths.
Significant (grade 3 or above) leucopenia was more common in cohort B than in cohort A (9% and 1% respectively); there were more dose
reductions, and the median administered dose intensity was lower in cohort B than in cohort A (89% and 97% respectively; P =0.006). In this
group of relatively unselected patients, we have confirmed a relatively low objective response rate and median survival of 7.8 months with this
regimen. There was no significant difference in outcome between the two dose levels but the higher dose of 5-FU was associated with more
dose reductions and greater toxicity.
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Colorectal cancer is second only to bronchial carcinoma as a cause
ofcancer death in the UK. There are currently 28 000 new cases in
the UK each year, and around halfofthese patients will die within
5 years of diagnosis. A meta-analysis of 5-fluorouracil (5-FU)
used alone in a conventional bolus schedule showed a disap-
pointing response rate of 11% (Advanced Colorectal CancerMeta-
analysis Project, 1992).
A major locus of action of 5-FU is the enzyme thymidylate
synthase (TS), which is responsible for the formation of dTMP
from dUMP. The 5-FU metabolite FdUMP is a potent inhibitor of
TS, forming an irreversible ternary complex with TS and the
cofactor 5,10-CH2-tetrahydrofolate (5,10-CH2-FH4). Reduced
intracellular concentrations of 5,10-CH2-FH4 may therefore limit
the formation of the ternary complex and hence limit cytotoxicity
of5-FU. This hypothesis provides the rationale forthe use of5-FU
in combination with folinic acid (5-CHO-FH4), which is readily
converted to 5,10-CH2-FH4, increasing the formation of the
ternary complex. A meta-analysis of trials of 5-FU with folinic
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nation (Advanced Colorectal CancerMeta-analysis Project, 1992).
One internationally used schedule for the combination of 5-FU
and folinic acid was developed by De Gramont et al (1988). They
described a 48-h regimen in which a 2-h infusion of folinic acid
(200 mg m-2) is followed by bolus (300-500 mg m-2) 5-FU and
then a 22-h infusion (300-500 mg m-2) of 5-FU. This schedule is
repeated on day 2 and repeated at 2-weekly intervals. In the initial
phase II study of37 patients, there was a response rate of54% (CI
38-70%), and the regimen was well tolerated with no patients
experiencing WHO grade 3 toxicity (De Gramont et al, 1988). A
second phase II study in 43 patients confirmed this tolerability but
showed a lower response rate of24% (CI 11-37%) (Johnson et al,
1991). We reported previously a retrospective analysis of this
combination using 300-500 mg m-2 of 5-FU and found a disap-
pointing response rate of 11% (95% CI 4-18%) in 81 evaluable
patients (Jodrell et al, 1994). We noted, however, that patients
treated at the highest dose (500 mg m-2) of5-FU had a statistically
better median survival compared with those treated at 300-
400 mg m-2 of 5-FU after adjusting for the effects of other prog-
nostic factors (9 months and 5 months respectively, P = 0.001). In
view of this possible effect of 5-FU dose on outcome, we
performed a prospective study ofthis regimen at 500 mg m-2 of5-
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Figure 1 Graphical representation of the triangular test
FU. We used the relatively new approach of a group sequential
tringular procedure for response analysis. If the low response rate
seen in our retrospective study was confirmed, the dose of 5-FU
was to be increasedby 20% upto 600 mg m-2. The group sequential
triangular procedure was to be used again to confirm the response
rate at this higher dose level. A secondary aim of the study was to
assess toxicity ofthe regimen at these two dose levels.
PATIENTS AND METHODS
All patients had histologically proven colorectal cancer with
locally advanced, unresectable disease or metastases. Patients with










\..u+ .8tudy overruns and recruits
94 Ivauablepatients I I I I Il
0 20
-15
brain metastases or who had received prior intravenous 5-FU
chemotherapy (either adjuvant or for advanced disease) were
excluded. They were required to have WHOperformance status of
0, 1 or 2, with adequate renal function and bone marrow reserve,
and bidimensionally measurable disease by clinical examination
ofsoft-tissue metastases or radiological imaging with X-ray, ultra-
sound, CTScan or magnetic resonance imaging (MRI). Standard
WHO response criteria were applied (Miller et al, 1981). Patients
were eligible irrespective of derangement of liver biochemistry.
Before study entry, all patients had a full clinical examination;
WHO performance status recorded; and full blood count, plasma
biochemical profile, carcinoembryonic antigen (CEA) and CXR
taken. Toxicities during treatment were recorded every 2 weeks by
medical staff according to CTC criteria. This prospective study
was approved by the local ethics committee.
Treatment was given as an inpatient on days 1 and 2 ofa 14-day
cycle. On each treatment day, patients first received 200 mg m-2 of
folinic acid infused in 250 ml ofsaline over 2 h. This was followed
by a 15-min infusion of 5-FU in 100 ml of saline. The same dose
of5-FU was then given by infusion in 500 ml of saline over 22 h.
In the first cohort ofpatients, 500 mg m-2 of5-FU was given as the
bolus and infusion. For the second cohort of patients, the 5-FU
dose was increased by 20% to 600 mgm-2. Treatment was
repeated at 14-day intervals providing that toxicities had
resolved. Patients who had not recovered had treatment delayed
for 1 week. The protocol specified that, in those patients experi-
encing CTC grade III toxicity, the 5-FU dose was to be reduced to
75% and, for those patients with CTC grade IV toxicity, the 5-FU
was given at a 50% dose reduction. There was no dose reduction
offolinic acid.
Response to treatment was assessed by clinical examination or
radiologically (using the same imaging modality as that used for
the initial assessment) after four cycles (8 weeks) of treatment.
Tumour markers (CEA) and liver biochemistry tests were not
included as measures of objective response. Patients with progres-
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Figure 2 Graphical representation of the outcome of the triangular test for both dose cohorts
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a response continued for a further four cycles before reassessment.
After eight cycles, patients with stable disease or a response
continued with treatment at 2- or 4-weekly intervals at the physi-
cian's discretion.
Statistical methods
The paper describes the results oftwo consecutive phase II studies.
Both were designed to test the null hypothesis that the real
response rate was less than or equal to 25%, similar to the response
rate from the meta-analysis of 5-FU with folinic acid (Advanced
Colorectal Cancer Meta-analysis Project, 1992) against the alter-
native that it was greater than this. The response rate was similar to
the original result using this 5-FU schedule (De Gramont et al,
1988). In each case, the one-sided significance level for the test
was set at 2.5% and the power was set at 97.5% when the true
response rate was 40%. Both studies were conducted as group
sequential triangular tests (Bellissant et al, 1996). This test
involves plotting on the y-axis a statistic Z, which represents the
current difference between the observed response and the response
specified in the null hypothesis. On the x-axis is plotted the
statistic V, which represents the cumulative information gathered
on all patients so far assessed since the start of the trial. Two lines
on the graph delineate a triangular region (Figure 1), the coordi-
nates of which are determined by the power, significance level,
null and alternate hypotheses of the test. If at any time the plotted
point(x,y) falls within this triangular region, the study continues. If
the plotted point falls below the lower boundary the null hypoth-
esis is accepted. Alternatively, if the plotted point falls above the
upper boundary the null hypothesis is rejected. Here, the statistics
Z and V were calculated and plotted after response information
became available for each successive group of ten evaluable
patients in the 500 mg m-2 study and for each successive group of
20 evaluable patients in the 600 mgm-2 study. The group size was
increased in the second study to make the workload more practical
because of the rapid trial accrual. Both studies were set up and
analysed using the package PEST 2.2 (Whitehead and Brunier,
1989) using a transformation of the binomial parameter similar to
that in Whitehead (1982).
Overall survival and progression-free survival were calculated
from the date of study registration. All eligible patients were
included and deaths from all causes have been included in the
survival analysis. For progression-free survival, deaths from
disease were included, but causes of death unrelated to disease
progression were treated as censoring events. Kaplan-Meier esti-
mates (Parmar and Machin, 1995) were used to construct the
survival curves. Progression times were adjusted in the analysis to
occur atthe exact times specified for protocol response assessment
(every 8 weeks during chemotherapy and every 12 weeks during
follow-up). This was to overcome the problem of overestimating
the risk of progression by applying Kaplan-Meier techniques to
the unadjusted data (Peto, 1984). Survival curves were stopped
when fewer than five patients were at risk. Median follow-up times
were calculated using the reverse Kaplan-Meier method.
Prognostic factors for survival were identified by means of
Cox's proportional hazards model (Parmar and Machin, 1995)
using forward and backward stepwise selection techniques after
stratifying for study group. Cox's proportional hazard model was
also used for univariate survival comparisons. Prognostic factors
for response were identified by logistic regression (Armitage






Figure 3 Overall survival of both cohorts
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Figure 4 Progression-free survival of both cohorts
techniques. Ordinal categorical variables were compared using the
Mann-Whitney U-test (Armitage and Berry, 1987). The propor-
tion of patients responding were compared using Pearson's chi-
square test (Armitage and Berry, 1987) with no continuity
correction.
RESULTS
Patients (n = 206)
Between October 1992 and March 1994, a total of 107 patients
were treated at the 500 mgM-2 5-FU dose level (cohort A).
Between March 1994 and May 1995, a further 99 patients received
the 600mg m-2 5-FU dose (cohort B). The sequential procedure
indicated accrual to both cohorts could have ceased after each had
entered 60 evaluable patients (Figure 2). However, because of the
time required to confirm response data in these 60 patients and the
rapid trial accrual, the study did not close until additional patients
had been recruited in each cohort.
Pretreatment patient details for cohorts A and B are shown in
Table 1. Two patients had prior chemotherapy with intraperitoneal
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Table 1 Pretreatment patient details
Cohort A Cohort B




lnterquartile range 55-68 55-67
lime from initial diagnosis to starting study (weeks)
Median 35 39
Range 2-409 2-396
lnterquartile range 8-35 8-96
Site of primary tumour [% (n)]
Colon 69 (70) 60(54)
Rectum 31 (32) 40 (36)
Performance statusa [% (n)]
0 32 (32) 18 (16)
1 54 (55) 67 (60)
2 14(14) 16 (14)
Prior treatment [% (n)]
None 4(4) 0
Surgery only 79 (81) 74 (67)
Surgery and XRT 16 (16) 24 (22)
Surgery and chemotherapy 1 (1) 0
Surgery, XRT and chemotherapy 0 1 (1)
Initial alkaline phosphataseb [% (n)]
.ULN 10 (10) 3 (2)
>ULN 51 (50) 44 (36)
>2.5 x ULN 29 (29) 28 (23)
>5 x ULN 10 (10) 25 (20)
Initial WBC [% (n)]
<8.4 49 (50) 52 (47)
>8.5 51 (52) 48 (43)
Initial albumin [% (n)]
<LLN 20 (19) 16 (13)
>LLN 80 (75) 84 (68)
ap2 0.07, bp= 0.008 (Mann-Whitney U-test). ULN, upper limit normal; LLN,
lower limit normal; XRT, radiotherapy.
5-FU and intrahepatic doxorubicin. The two cohorts were not
randomized but were generally well matched. There were more
patients in cohort A of performance status 0 (32% vs 18%), but
this did not reach statistical significance (P = 0.07). Patients in
cohort A had significantly lowerinitial alkaline phosphatase levels
than those in cohort B (P = 0.008). There was no difference in the
number ofpatients with metachronous vs synchronous disease or
those with locally advanced vs metastatic disease between the two
cohorts. Of the 206 patients entered overall, five in cohort A and
nine in cohort B were ineligible and were not analysed further for
either toxicity orefficacy (n = 192 eligible). Ofthese 14 ineligible
patients, nine had no measurable disease, two had no histological
verification, one had prior 5-FU therapy, one had coexistent
Hodgkin's disease and one patient was treated with an inappro-
priate dose of5-FU (550 instead of600 mg m-2).
Efficacy (n = 179)
Ofthe 192 eligible patients, eight and five patients in cohort A and
B, respectively, were not evaluable for response because of the
lack ofrepeat assessment with scans. In the 179 evaluable patients
Table 2 Toxicity, i.e. worst CTC grade recorded with any course
CTCgrade 0 1 2 3 4
Mucositis (%)
Cohort A 61 23* 12 4 0
Cohort B 39 41* 12 8 0
Leucopenia (%)
Cohort A 78 16 7 1 0*
Cohort B 60 10 12 4* 4*
Diarrhoea (%)
Cohort A 62 21 14 4 0
Cohort B 57 19 18 6 1
Nausea (%)
Cohort A 53 34 11 2 0
Cohort B 50 34 12 3 0
Vomiting (%)
Cohort A 77 11 8 4 0
Cohort B 77 11 10 2 0
*P. 0.01
in both cohorts, only ten (6%) achieved a complete response. A
further 22 patients (12%) had an objective partial response, giving
an overall response rate of 18% (95% CI 12-24%). Seventy-nine
patients (44%) had stable disease (SD) and 68 patients (38%) had
progressive disease. There was no difference between cohort A
and B either in response rate (18% for both; P= 0.94) or in
frequency of SD (45% and 44% respectively). Raised initial alka-
line phosphatase and WBC were associated with lower response
rate on univariate analysis (P = 0.03 and 0.001 respectively).
However, on multivariate analysis, only the initial WBC (< 8.5 vs
>8.5) was associated with poor response rate (P = 0.002). The 93
patients with a WBC of < 8.5 had a response rate of 28%
compared with 7% in the 86 patients with a WBC >8.5.
To date, a total of 150 patients have died. In cohort A, there are
ten patients still alive and the median follow-up is 110 weeks
compared with 32 alive and a median follow-up of 57 weeks for
cohort B. The overall median survival was 7.8 months (i.e. 34
weeks, 95% CI 30-39 weeks), with no significant difference
between median survival in the two5-FU cohorts (32 and 37 weeks
for cohorts A and B respectively) as shown in Figure 3 (P =0.27).
Figure 4 shows progression-free survival ofall patients by 5-FU
dose cohort. Median progression-free survival is 16 weeks in both
cohorts. The difference in progression-free survival between
cohort A and B was not statistically significant with an adjusted
progression rate ratio of0.85 (95% CI 0.62-1.18, P = 0.34).
On univariate analyses, the following factors were associated
with shorter survival: poor performance status (P<0.001), raised
initial alkaline phosphatase (P<0.001), CEA (P=0.04), WBC
(P <0.001), bilirubin (P =0.007) orAST (P = 0.01) and low haemo-
globin (P = 0.01) or albumin (P < 0.001). On multivariate analysis,
low albumin (P<0.001), raised WBC (P< 0.001), raised aLkaline
phosphatase (P= 0.05) and poor performance status (P= 0.03)
retainedsignificance. Theforwardandbackward selectiontechniques
produced the same result forboth the Cox and the logistic regression
analyses. Adjusting for prognostic factors between the two cohorts,
the difference in survival was not statistically significant, with an
estimated death rate ratio of0.77 (95% CI 0.54-1.11, P=0.16).
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Table 3 Reasons for dose reductions
Cohort A Cohort B
Percentage of patients with dose reduction 17 41
Total number of cycles reduced 18 44
As per protocol - grade 3/4 toxicity As per Protocol As per Protocol
Protocol violations - grade 2 toxicity protocol violation protocol violation
8 10 15 29
Reasons for reductions
Haematological 0 2 5 6
Mucositis 2 4a 3 7
Diarrhoea 2 3 3 8
Nausea/vomiting 2 1 1 2
Hand-foot syndrome 2 0 2 8b
Other 0 0 2 2
aOne patient with grade 1 mucositis. bTwo patients with grade 1 hand-foot syndrome. Note, five patients had more than one reason for dose reduction.
Toxicity (n = 192)
There were no treatment-related deaths. Significant toxicities are
shown in Table 2. Significant leucopenia (CTC grade 3 or above)
was more common in cohort B than in cohort A (8% and 1%
respectively, P = 0.01). This was associated with three episodes of
neutropenic sepsis (two of which required hospital admission) in
two patients in cohort B. No patient experienced grade 3 or 4
thrombocytopenia. In cohort B, 61% ofpatients experienced some
degree of mucositis compared with only 39% of cohort A. This
was principally due to a higher incidence of grade 1 mucositis in
cohort B (P = 0.01). Similarly, grade 1 or 2 alopecia was more
common in cohort B (44% vs 21%, P = 0.001), but no patient
experienced grade 3 alopecia. Clinically significant, i.e. grade 2 or
above, hand-foot syndrome was more common in cohort B than
cohort A, but this difference was not statistically significant (9%
and 5% respectively, P = 0.27). Similarly there was no difference
in the rate of diarrhoea, nausea and vomiting experienced in both
cohorts, with only a small number ofpatients experiencing grade 3
or 4 toxicity.
Dose intensity
A median of five cycles was given to patients in both cohorts.
Eighty-five per cent ofpatients (81% and 90% ofcohort A and B
respectively) stopped treatment at or before eight cycles. The
reasons for stopping were: progressive disease (54%); excessive
toxicity (9%); death from otherunrelated causes (4%); completing
eight cycles (11%); and other 'miscellaneous reasons' (22%).
Treatment delays were similar for both cohorts with 11% of all
cycles delayed in 42% of all patients. Of the 125 cycles delayed,
35 were for haematological toxicity, 25 for non-haematological
toxicity, 25 fordisease-related conditions and the remaining 40 for
mostly administrative reasons, such as public holidays.
There was, however, a significant difference in the median
percentage of administered relative to intended dose intensity
between cohort A and B (97% and 89% respectively, P = 0.006).
This was due to more patients in cohort B than cohort A having
dose reductions (41% and 17% respectively). In cohort A, 67% of
patients received at least 90% ofthe intended dose intensity of 5-
FU compared with only 48% in cohort B. In view ofthis difference
in dose reductions, despite the lack of a statistically significant
increase in objective toxicity between the two cohorts, the reasons
for the dose reductions in each cohort were examined further.
Although some ofthese dose reductions were not specified by the
protocol, in each case they resulted from clinically significant
toxicities as shown in Table 3.
The greater number of dose reductions in cohort B mean that
there was an increase of only 10% in the administered dose of 5-
FU between the two cohorts instead of the 20% that had been
intended. Therefore, we also examined whether the actual deliv-
ered 5-FU dose intensity influenced response or survival. Dividing
the patients into three equal-sized cohorts by the actual 5-FU dose
given, i.e. < 948 mg of 5-FU m-2 per week (n = 64), > 948 up to
1018 mg of 5-FU m-2 per week (n = 65) and > 1018 mg of 5-FU
mi-2 per week (n = 63), there was no association between actual 5-
FU dose given and survival, progression-free survival or response,
even when stratified for the number of cycles received and
prognostic factors (data not shown).
DISCUSSION
In thisprospective dose escalation phase II study ofbolus/infusional
5-FU and folinic acid, we have shown, in a relatively unselected
group ofpatients with metastatic or advanced colorectal carcinoma,
a response rate of only 18% and a median survival of just 7.8
months. In the retrospective analysis performed at our unit (Jodrell
et al, 1994), three different doses of 5-FU from 300-500 mg m-2
were used. In that study, we found that the higher 5-FU dose of
500 mg m-2 was associated with an improved median survival of 9
months compared with a median survival of 5 months at the lower
doses (relative hazard = 0.38, 95% CI 0.21-0.70) afteradjusting for
the effects of PS, age, PALA, primary site and liver function. The
current prospective study has not confirmed an effect of5-FU dose
over 500 mg m-2 on outcome in this population ofpatients.
There are now several reports of this 48-h bolus/infusional 5-
FU-folinic acid regimen. A striking feature of these studies is the
wide variation in response rates and survival that have been
reported. The initial phase II report of this regimen described a
response rate of 54% (95% CI 38-70%) and a median survival of
18 months (De Gramont et al, 1988). In a subsequent prospective
randomized study (De Gramont et al, 1995), 177 evaluable patients
were given this regimen, and the response rate was somewhat
lower at 32% (95% CI 25-39), with a median survival of 14
months. In broad agreement with these data, two prospective phase
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II trials showed a response rate of24% (95% CI 11-37%) and 38%
(95% CI 28-48%) and median survival of 17.3 and 10.3 months
respectively (Johnson et al, 1991; Becouam et al, 1995). By
contrast, the results in the current study are similar to those from
two retrospective studies of this regimen, both of which had a
response rate ofonly 11% (95% CI4-18%) and median survival of
6 months (Jodrell et al, 1994) and 8 months (Hanna et al, 1995).
Patient selection is the most probable explanation for these
differences. The patients entered into the formal phase II and III
studies (De Gramont et al, 1988; 1995; Johnson et al, 1991;
Becouam et al, 1995) may have differed significantly from those
in the current study and the retrospective audits (Jodrell et al,
1994; Hanna et al, 1995). The studies are difficult to compare as,
unfortunately, not all have described prognostically important
patientcharacteristics. Forexample, initial liverbiochemistry tests
are not widely quoted, although these have been identified as
influencing prognosis (Petrelli, 1995). The current study hadbroad
entry criteria, with no limits on liver dysfunction, and it accrued
patients from 16 oncologists at the Beatson Oncology Centre,
serving most ofthe population of the West of Scotland. The rela-
tively low response rate and survival in the current study, in line
with that of the retrospective studies (Jodrell et al, 1994; Hanna
et al, 1995) probably more accurately reflects the impact of this
regimen on the general population of patients with advanced
colorectal cancer.
A further difference between the studies is the duration oftreat-
ment and timing ofresponse assessment. We first assessed patients
after only four treatments (i.e. 8 weeks) and again aftereight treat-
ments, whereas some groups assessed patients after six and 12
treatments (De Gramont et al, 1988; Johnson et al, 1991). Early
assessment may result in patients stopping treatment prematurely,
before a response is noted. In particular, Hanna et al (1995)
suggested that continued treatment in patients with stable disease
may account for some of the differences between the studies.
Indeed, patients in one study with a high response rate (Becouam
et al, 1995) received a mean of ten cycles. However, in other
studies with high response rates, the average number of cycles
given was five (Johnson et al, 1991; De Gramont et al, 1995). This
compares with a median of five cycles given in the current study
and four cycles in another with a low response rate (Hanna et al,
1995). It is unclear what proportion ofpatients with stable disease
after four cycles oftreatment may go on to respond iftreatment is
continued. In the current study, one-third of the responses were
first noted only after eight cycles of treatment. Only 15% of our
patients continued treatment beyond eight cycles and just one
subsequently responded. Graf et al (1994) have suggested a
survival advantage of4 months for patients with stable disease on
chemotherapy in their analysis of the relationship between
response to chemotherapy and survival in advanced colorectal
cancer. Of those patients who stopped at or before eight cycles of
treatment, 54% had progressive disease and a further 9% stopped
because of toxicity. The remaining third of patients who stopped
had stable disease or a response but stopped chemotherapy either
on the clinician's recommendation (11%) or for other reasons,
most often patient request (22%). This suggests that it may be
difficult to continue 2-weekly treatment beyond eight cycles in
this relatively unselected group ofpatients underthe care ofa large
number ofdifferent clinicians.
Although there were minor differences in toxicities between the
two cohorts, this was not enough to account for the significant
difference in dose reductions in cohort B compared with cohort A
(41% and 17% respectively). Nevertheless, there was still a differ-
ence in median 5-FU dose per week of 970 mg m-2 per week in
cohort A and 1068 mg m-2 per week in cohort B (an increase of
10% in 5-FU dose). On reviewing these dose reductions, most
were the result of toxicities, recorded as minor by the clinician,
that patients found to be unacceptable, e.g. persistent grade 1
mucositis or grade 2 hand-foot syndrome. This perhaps reflects
more the realistic level of acceptable toxicity of palliative
chemotherapy in this setting. We did, however, confirm the low
incidence ofgrade 3 or above toxicity with this regimen found by
others. The numberofdose reductions and delays is only quoted in
two ofthe other studies (Jodrell et al, 1994; Hanna et al, 1995).
The primary aim of this report is to evaluate the effect of 5-FU
dose on treatment outcome. This study was the combination oftwo
sequential phase II studies to determine outcome at500 and 600mg
m-2 of 5-FU. The response rate for each of these studies was
performed using a group sequential triangular procedure. This
involves examining the response rate in consecutive cohorts of
patients (in this case ten or 20) and is a relatively novel approach to
clinical evaluation ofcancer treatment. In both cohorts, the sequen-
tial triangular test indicated closing each cohort after response
results became evaluable for the first 60 evaluable patients (Figure
2). Because of rapid accrual and delays in obtaining response
assessments, data were available only after additional patients had
been recruited. This 'overshoot' was not described in a previous
report ofthe use ofthe group sequential triangular test (Dieras et al,
1996). We were collecting response data on patients whose scans
were performed over the entire West of Scotland, and this led to
understandable delays. This practical issue of the commitment
needed for the rapid collection ofresponse data should be noted by
other groups wishing to use this method of analysis. Nevertheless,
using the sequential triangular test in our study, we have calculated
that we entered 59% fewerevaluable patients than wouldhavebeen
required for the two equivalent phase II studies for the response
rates and confidence intervals seen.
A formal comparison of the two 5-FU dose levels would opti-
mally be made using a randomized study, whereas we report two
consecutive phase II studies. When the results ofcohort A became
available, a randomized study was considered. However, some
clinicians felt that, in view of the low response rate with 500 mg
m-2 5-FU, and the possibility of a dose-response effect (Jodrell et
al, 1994), they preferred to investigate the 600 mg m-2 dose level
in a further phase II study. Nevertheless, the two cohorts were well
matched, although we did see significantly more patients with a
raised alkaline phosphatase and fewer patients with performance
status 0 in cohort B. After adjusting for prognostic factors,
including alkaline phosphatase and performance status, there was
a trend towards increased survival in cohort B compared with
cohort A, with a death rate ratio of 0.77, but this was not signifi-
cant (95% CI 0.54-1.11, P = 0.16). It is disappointing that we
found a very consistent low response rate of 18% and median
survival of 7.8 months in both cohorts. Although dose reductions
in cohort B meant that we achieved a dose increase of only 10%,
rather than the 20% intended, we have no good evidence from this
study to support increasing the dose of 5-FU from 500 to
600 mg m-2. Indeed, taken with the results of our previous study
(Jodrell et al, 1994), we have found a ceiling of5-FU dose effect at
500 mg m-2, with further dose increases difficult to administer in
this group ofpatients.
Although response rates and survival using this 48-h bolus/infu-
sion regimen may be lower in a general population than initially
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reported, in a randomized study (De Gramont et al, 1995) it did
achieve a higher response rate than a monthly 5-day bolus 5-FU
regimen (32.2% and 13.8% respectively, P = 0.002). However,
even in that study, there was no significant difference in overall
median survival between the two groups (61 and 58 weeks respec-
tively) and a benefit of only 5 weeks in progression-free survival
with the 48-h regimen (26.7 and 21.6 weeks respectively, P =
0.007). In this palliative setting with relatively minor differences
between regimens, the fundamental issue is the quality of life of
these patients. We collected no quality oflife data on this group of
patients, and there was no formal assessment of quality of life
in any of the previous six studies on this regimen. However,
Becouam et al (1995) state that 74% of symptomatic patients had
an improvement of their symptoms on the regimen. Likewise,
Johnson et al (1991) stated that performance status rose in 60% of
patients and 70% reported a subjective improvement in overall
well-being with treatment. Hanna et al (1995) indicated that in
their study 12% ofthe non-responding patients improved sympto-
matically during chemotherapy. These data suggest that with 44%
of our patients having stable disease, we may have significantly
underestimated the benefit of this regimen in terms of symptom
control. It is important that future studies address the issue of
quality of life, and this is a central part of the MRC trial of this
regimen compared with continuous infusional 5-FU andTomudex,
which will also include cost benefit analysis.
In conclusion, we have used anovel trial methodology, the group
sequential design, to investigate two dose levels of5-FU given as a
48-h regimen. We found a response rate of 18% and a me,dian
survival of7.8 months with this regimen in a relatively unselected
group of patients with advanced colorectal carcinoma. These
results may be explained in part by patient selection and treatment
duration. These data suggest that increasing the dose intensity of
this regimen is unlikely to improve outcome. Rather, itis important
to compare this 48-h 5-FU schedule with otherregimens in terms of
response, survival and quality of life in prospective randomized
trials before being accepted as routine clinical practice.
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